Liraglutide, 7,8-DHF and their co-treatment prevents loss of vision and cognitive decline in a Wolfram syndrome rat model
Abstract Wolfram syndrome (WS) is a monogenic progressive neurodegenerative disease and is characterized by various neurological symptoms, such as optic nerve atrophy, loss of vision, cognitive decline, memory impairment, and learning difficulties. GLP1 receptor agonist liraglutide and BDNF mimetic...
Enregistré dans:
Auteurs principaux: | Kadri Seppa, Toomas Jagomäe, Kaia Grete Kukker, Riin Reimets, Marko Pastak, Eero Vasar, Anton Terasmaa, Mario Plaas |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/e93aa6c7d66f4066a7c2017128bcf2ce |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
par: Toomas Jagomäe, et autres
Publié: (2021) -
The Expression of RAAS Key Receptors, <i>Agtr2</i> and <i>Bdkrb1</i>, Is Downregulated at an Early Stage in a Rat Model of Wolfram Syndrome
par: Marite Punapart, et autres
Publié: (2021) -
The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome
par: Fiorenza Stagni, et autres
Publié: (2021) -
Early brain vulnerability in Wolfram syndrome.
par: Tamara Hershey, et autres
Publié: (2012) -
BILATERAL ATROPHIC MACULOPATHY IN TWO SIBLINGS OF WOLFRAM SYNDROM
par: Tayyab Azeem Janjua, et autres
Publié: (2018)